Merck & Co., Inc. (MRK) SEC Filings & Earnings Calls

Drug pricing pressure from IRA and other government actions

“Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide.” · word for word

Generic competition for key products

“Januvia and Janumet lost market exclusivity in the U.S. in May 2026 and Janumet XR lost market exclusivity in the U.S. in July 2026.” · word for word

China market weakness for Gardasil

“As previously disclosed, the Company suspended shipments to China in February 2025 given lower demand and elevated channel inventory levels in China.” · word for word

IRS tax dispute

“In April 2025, Merck received Notices of Proposed Adjustment (NOPAs) that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries by approximately $1.3 billion.” · word for word

Vaccine market contraction

“Additionally, the overall U.S. vaccines market has experienced a contraction negatively affecting sales.” · word for word

Large R&D expense ($9.7B in Q2) driving GAAP loss; includes significant acquisition-related costs and restructuring

“Research and development 9,741 (Q2 2026) vs 4,048 (Q2 2025). GAAP net loss $(1,335)M.”

Keytruda sales decline 1% YoY due to Qlex cannibalization; patent cliff risk remains

“Keytruda 7,904 vs 7,956 (-1%). Keytruda Qlex 463 (new, partially cannibalizing).”

IRA Drug Price Negotiation Expansion

“the Company expects that Keytruda (pembrolizumab) will be selected in 2027 for government price setting, which would become effective on January 1, 2029.” · word for word

Patent Expiry / Loss of Exclusivity

“the Company anticipates it will lose nearly all U.S. sales of Januvia and Janumet .” · word for word

China Demand and Regulatory Risk

“the Company suspended shipments to China beginning in February 2025 given lower demand and elevated channel inventory levels in China.” · word for word

IRS Tax Dispute

“Merck received Notices of Proposed Adjustment (NOPAs) that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries by approximately $1.3 billion.” · word for word

Pipeline Setbacks

“the Company has decided to end the MK-1308A clinical development program” · word for word

GARDASIL decline in China

“GARDASIL/GARDASIL 9 sales declined 19% primarily due to lower demand in China”

Generic competition for JANUVIA

“JANUVIA/JANUMET sales declined 28% due to generic competition”

Keytruda LOE Risk

“Our results reflect the strength of our oncology and Animal Health businesses, increasing contributions from new launches, and meaningful progress in transforming our expanding innovative portfolio for sustainable, long-term growth.” · word for word

Vaccine Revenue Decline

“Revenue increase in 2025 driven by growth in Oncology, Cardiometabolic & Respiratory, Diabetes, and Animal Health, largely offset by declines in Vaccines, Immunology, and Virology” · word for word

Pricing Pressure

“The costs associated with innovation are increasing while relative return is decreasing due to ongoing pricing pressure.” · word for word

IRA Drug Price Negotiation

“The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), selected Januvia in 2023 for the first year of the IRA’s “Drug Price Negotiation Program”... and selected Janumet and Janumet XR in 2025 for the second year of the IRA’s Program.” · word for word

China Gardasil Demand Risk

“Combined worldwide sales of Gardasil and Gardasil 9... declined 39% in 2025 primarily driven by lower demand in China... the Company made a decision to temporarily pause shipments to China beginning in February 2025.” · word for word

Keytruda Biosimilar Competition

“a biosimilar of Keytruda has launched in Argentina.” · word for word

Bridion Loss of Exclusivity

“Bridion will lose market exclusivity in the U.S. in July 2026 at which time the Company anticipates a significant and rapid decline in U.S. sales of Bridion.” · word for word

Most-Favored-Nation Pricing Agreement

“the Company announced that it had entered into a three-year agreement (MFN Agreement) with the U.S government that addressed the four policy goals of the administration’s July letter.” · word for word

Gardasil sales declined 34% due to lower international demand.

“Gardasil/Gardasil 9 $1,031M, down 34%; International down 47%.”

GAAP profitability impacted by restructuring and acquisition costs.

“Restructuring costs $213M in Q4; GAAP net income down 21%.”

Increased leverage from $8.0B debt issuance; interest expense will rise, but maturities are long-dated (2029-2065).

“Issued $8.0B in notes with coupons from floating rate to 5.700% due 2065.”

IRA drug price negotiation

“Pursuant to the IRA’s Program, a government price was set for Januvia, which will become effective on January 1, 2026.” · word for word

China demand decline for Gardasil

“the Company made a decision to temporarily pause shipments to China beginning in February 2025 and, given continued lower demand and elevated inventory levels in China, in mid-2025, the Company determined it would not make any further shipments to China through at least the end of 2025.” · word for word

Patent expiries

“the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026” · word for word

IRS tax dispute

“Merck received Notices of Proposed Adjustment (NOPAs) that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries by approximately $1.3 billion.” · word for word

Tariff impact

“the Company anticipates that tariffs implemented to date will result in less than $100 million of additional expenses in 2025” · word for word

Gardasil sales decline 24% YoY, driven by international weakness (-54%).

“Gardasil/Gardasil 9 $1,749M, -24% YoY; International -54%.”

Lagevrio sales decline 64% YoY as pandemic demand wanes.

“Lagevrio $138M, -64% YoY.”